Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
VBI Vaccines Inc/BC (VBIV)
Sector: Healthcare; Industry: Biotechnology

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. It primarily serves physicians and pharmacists through direct sales. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2019-10-04 Diaz-Mitoma Francisco Chief Medical Officer Buy 54,500 $0.50 $27,250 No
2019-06-27 Diaz-Mitoma Francisco Chief Medical Officer Buy 8,000 $1.07 $8,560 No
2019-06-20 Diaz-Mitoma Francisco Chief Medical Officer Buy 52,000 $0.87 $45,180 No
2018-08-03 Diaz-Mitoma Francisco Chief Medical Officer Buy 9,000 $2.13 $19,200 No
2018-05-11 Diaz-Mitoma Francisco Chief Medical Officer Buy 10,000 $3.05 $30,475 No
2017-08-21 Diaz-Mitoma Francisco Chief Medical Officer Buy 3,000 $3.17 $9,510 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

VBI Vaccines Inc (VBIV) - Since 10%-owner Perceptive Advisor LCC increased their holding in April, the stock have double the price. Impressive!